OliPass Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 27

Employees

  • Stock Symbol
  • 244460

Stock Symbol

  • Share Price
  • $1.13
  • (As of Monday Closing)

OliPass General Information

Description

Olipass Corp is a South Korea based biotechnology company engaged in developing its platform OliPass PNA which focuses on introducing cationic lipid moiety onto nucleobase. Its pipeline products include SC Injection, Hyper Cholesterolemia, Chemo/Radio-sensitizer, and Type II Diabetes among others.

Contact Information

Website
www.olipass.com
Formerly Known As
CTI Bio
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Ace Dongbaek Tower 20th Floor
  • 16 Beon, 16-4 Dongbaek Jungang, Giheung Yongin
  • Yongin, Gyeonggi 17015
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Stock Exchange
KRX
Vertical(s)
Life Sciences
Corporate Office
  • Ace Dongbaek Tower 20th Floor
  • 16 Beon, 16-4 Dongbaek Jungang, Giheung Yongin
  • Yongin, Gyeonggi 17015
  • South Korea
+82

OliPass Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OliPass Stock Performance

As of 07-Apr-2025, OliPass’s stock price is $1.13. Its current market cap is $6.14M with 5.44M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.13 $1.32 $1.07 - $6.85 $6.14M 5.44M 240K -$1.00

OliPass Financials Summary

As of 31-Dec-2025, OliPass has a trailing 12-month revenue of $573K.

In Thousands,
USD 		TTM 31-Dec-2025 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 21,554 17,959
Revenue 573 573 554 4,346
EBITDA (6,220) (6,220) (2,854) (11,839)
Net Income (10,809) (10,809) (3,897) (9,593)
Total Assets 12,013 12,013 17,841 10,606
Total Debt 6,341 6,341 5,323 2,785
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OliPass Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore OliPass‘s full profile, request access.

Request a free trial

OliPass Patents

  • 84

    Total Documents Applications and Grants

  • Total Patents Families

  • 47

    Granted

  • 11

    Pending

  • Expiring in next 12 mo

OliPass Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3999523-A1 Melanophilin antisense oligonucleotides Inactive 18-Jul-2019
EP-3999523-A4 Melanophilin antisense oligonucleotides Inactive 18-Jul-2019
US-20220363720-A1 Melanophilin antisense oligonucleotides Inactive 18-Jul-2019
WO-2021010723-A1 Melanophilin antisense oligonucleotides Inactive 18-Jul-2019
US-11739124-B2 Acetyl-coa carbosylase2 antisense oligonucleotides Active 14-Aug-2018 C07K14/003
To view OliPass’s complete patent history, request access »

OliPass Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OliPass Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore OliPass‘s full profile, request access.

Request a free trial

OliPass ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view OliPass’s complete esg history, request access »

OliPass FAQs

  • When was OliPass founded?

    OliPass was founded in 2006.

  • Where is OliPass headquartered?

    OliPass is headquartered in Yongin, South Korea.

  • What is the size of OliPass?

    OliPass has 27 total employees.

  • What industry is OliPass in?

    OliPass’s primary industry is Biotechnology.

  • Is OliPass a private or public company?

    OliPass is a Public company.

  • What is OliPass’s stock symbol?

    The ticker symbol for OliPass is 244460.

  • What is the current stock price of OliPass?

    As of 07-Apr-2025 the stock price of OliPass is $1.13.

  • What is the current market cap of OliPass?

    The current market capitalization of OliPass is $6.14M.

  • What is OliPass’s current revenue?

    The trailing twelve month revenue for OliPass is $573K.

  • What is OliPass’s annual earnings per share (EPS)?

    OliPass’s EPS for 12 months was -$1.00.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process